Background Image
Menu

News: 2021

Cambridge Cognition completes spin-out of Monument Therapeutics

1 July 2021

Cambridge Cognition completes spin-out of Monument Therapeutics

Manchester, UK, July 1st, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised £2.625 million in seed funding to spin out of Cambridge Cognition Ltd and relocate to Alderley Park, Cheshire. The new company will focus on applying digital...

Infinity BiologiX and Cytox collaborate to provide new genetic test to predict the risk of cognitive decline due to Alzheimer’s Disease

24 June 2021

Infinity BiologiX and Cytox collaborate to provide new genetic test to predict the risk of cognitive decline due to Alzheimer’s Disease

Powered by Cytox’s genoSCORE, the new test enables physicians to support patients with lifestyle changes, and guide possible use of drug therapy, to delay the onset of disease symptoms … PISCATAWAY, N.J. & OXFORD, England & MANCHESTER, England--(BUSINESS...

Rinicare to provide continuous vital signs monitoring technology to Indian healthcare system

17 June 2021

Rinicare to provide continuous vital signs monitoring technology to Indian healthcare system

Manchester-based medtech start-up Rinicare has signed a deal with its distribution partner, Rinicom, to build and deliver an initial 100 units of its continuous vital signs monitoring technology to the Indian healthcare system. Corelink India will be distributing the units...

Innovate UK funds AssistDent adaption for university dental schools

16 June 2021

Innovate UK funds AssistDent adaption for university dental schools

COVID-19 has placed major strains on dental schools where the practical, patient-orientated elements have faced significant challenges during lockdowns. Recognising the importance and ongoing impact of these issues Innovate UK, the UK’s innovation agency, has awarded...

Blueberry Therapeutics secures further investment

9 June 2021

Blueberry Therapeutics secures further investment

NPIF – Maven Equity Finance, managed by Maven Capital Partners (“Maven”) and part of the Northern Powerhouse Investment Fund (“NPIF”) has invested £750,000 in Blueberry Therapeutics Limited (“Blueberry”), a drug discovery and...

Infex Therapeutics partners with Alderley Analytical

26 May 2021

Infex Therapeutics partners with Alderley Analytical

Alderley Park, Cheshire Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and ADA analysis of Infex’s RESP-X program. RESP-X is an anti-virulence therapy in-licensed from Japanese pharma company Shionogi. It is designed to help the body...

INFEX Therapeutics appoints Lonza to manufacture new lung infection drug

17 May 2021

INFEX Therapeutics appoints Lonza to manufacture new lung infection drug

Alderley Park, Cheshire - Infex Therapeutics has awarded a £1m contract to Lonza to help progress its RESP-X program, a novel therapy which targets serious recurrent respiratory infections in patients with damaged lung functions. RESP-X is expected to enter clinical trials...

Digital health start-up Clin-e-cal launches free app to help improve inhaler technique and reduce asthma attacks

10 May 2021

Digital health start-up Clin-e-cal launches free app to help improve inhaler technique and reduce asthma attacks

Manchester-based digital health start-up Clin-e-cal has launched a free app to help people with respiratory diseases to monitor and improve their inhaler technique. The Clip-Tone Buddy app is the first digital solution which can provide real time feedback and effectively guide a...

British Pharmaceutical Company Maxwellia Secures Government Future Fund investment to Spearhead Shift in Self-Care

4 May 2021

British Pharmaceutical Company Maxwellia Secures Government Future Fund investment to Spearhead Shift in Self-Care

Maxwellia, a pioneering British business that is poised to transform the UK’s self-care market through its specialist model of making more medicines available to buy from UK pharmacies has received a £500k investment from the UK Government via conversion of its...

Panthera becomes the world’s first clinical trial site to administer Valneva’s inactivated COVID-19 vaccine (VLA2001) to volunteers in phase 3 study

29 April 2021

Panthera becomes the world’s first clinical trial site to administer Valneva’s inactivated COVID-19 vaccine (VLA2001) to volunteers in phase 3 study

Panthera has today, (28thApril 2021) started vaccinating volunteers in Valneva’s double-blind, phase three, COVID prevention trial. The trial will compare Valneva’s inactivated vaccine, VLA2001, with AstraZeneca’s conditionally approved vaccine Vaxzeria. Unlike...